

ORCHID PHARMACEUTICALS, INC AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEET

	<b>March 31, 2023</b>
<b>Assets</b>	
<b>Current Assets:</b>	
Cash	\$4,97,335
Accounts Receivable, Net of allowances	\$3,09,292
Due from Bionpharma	\$3,96,364
Inventory	\$0
Prepaid Expenses & Deposits	\$18,651
	<hr/>
Total current assets	\$12,21,642
Fixed Assets, net	\$4,615
Due from Orchid Europe Ltd.	\$0
Due from Diakron and Bexel, Affiliated Companies	\$2,36,489
	<hr/>
<b>Total Assets</b>	<b>\$14,62,746</b>
	<hr/> <hr/>
<b>Liabilities and Stockholders' Equity</b>	
<b>Current Liabilities:</b>	
Accounts Payable, Trade	\$42,000
Accounts Payable, Orchid Pharma Ltd.	\$56,23,522
Other Liabilities Due to Orchid Pharma Ltd.	\$12,71,779
Accrued expenses	\$4,27,759
Income Taxes Payable	\$2,342
Accrued Payroll Liabilities	\$1,215
	<hr/>
Total current liabilities	\$73,68,617
Loan payable Orchid Pharma Ltd.	\$25,03,600
	<hr/>
<b>Total Liabilities</b>	<b>\$98,72,217</b>
	<hr/> <hr/>
<b>Stockholders' deficit:</b>	
Common Stock	\$100
Additional Paid-In- Capital	\$2,00,000
Deficit	(\$86,09,571)
	<hr/>
<b>Total stockholders' deficit</b>	<b>(\$84,09,471)</b>
	<hr/> <hr/>
<b>Total liabilities and stockholders' deficit</b>	<b>\$14,62,746</b>
	<hr/> <hr/>

**ORCHID PHARMACEUTICALS, INC AND SUBSIDIARIES**

**P&L Account for the year 2022-23**

	<b>March 31, 2023</b>
<b>Income</b>	<hr/> \$0
<b>Ttoal</b>	<hr/> <b>\$0</b> <hr/>
<b>Expenses</b>	
<b>Balances written off</b>	
Due from Orchid Europe Ltd. Written off	\$6,92,470
	<hr/>
Deficit transferred to shareholders funds account	(\$6,92,470)
	<hr/> <hr/>